Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT02633553
Recruiting Not applicable

Adjuvant Radiotherapy for Stage II/III Thymoma After Complete Resection

NCT02633553 · tracked via the Priya Life Science China tracker
Sponsor
Fudan University
Phase
Not applicable
Started
2018-01-10
Last updated
2026-04-24

Condition(s) studied

Thymoma

Investigational drug(s) / intervention(s)

adjuvant radiotherapy

adjuvant radiotherapy: 50Gy/25Fx

Study summary

This study is designed to investigate whether adjuvant radiotherapy after complete resection has a better survival for stage II or III thymoma.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: 18\~75 years old; Eastern Cooperative Oncology Group performance status of 0 to 2; Pathologically confirmed masaoka stage II or III thymoma; Have adequate bone marrow, hepatic, and renal function; Patients receive complete resection within 3 months; Written informed consent. Exclusion Criteria: Patients with distant metastases; Patients underwent radiotherapy or chemotherapy; Patients who have malignancy history excluding carcinoma in situ of cervix in the previous five years; Active clinical pulmonary infection; Pregnant or nursing.

Primary outcome measure(s)

  • DFS (Disease free survival) — 5 years
    from registration to disease progression or death.

Trial sites (1)

FacilityCityRegionStatus
Kailiang Wu Shanghai Shanghai Municipality Recruiting

More Fudan University trials in China

Real-world Study on the Management of Hematological Toxicities Associated With Targeted Therapies for Breast Cancer Recruiting
Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment Recruiting
Chemoradiotherapy and Anti-PD-1 Antibody in Anal Squamous Cell Cancer：Chase Recruiting
The Association Between Age-related Peripheral Blood Components and Treatment Efficacy in Breast Cancer Recruiting
Cola Ingestion for Esophageal Bolus Impaction Active, not recruiting

Other trials for the same condition

Electrocautery Resection Combined With HITHOC for Thymic Epithelial Tumors With Pleural Metastasis Starting soon
Robot-assisted vs VATS for Thymoma Recruiting
Glucocorticoids Combined With Concurrent Chemoradiotherapy for Unresectable Thymoma Recruiting
Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic Carcinoma Recruiting
Hypofractionated Radiotherapy for Thymic Epithelial Tumors Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02633553 on ClinicalTrials.gov ↗ ← All trials in China